GlassScriptPhysician profile
Michael J Odell
NPI 1477593143
$5,417.37
in general payments reported to CMS, 2019-2025
40 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $829 · 2021: $923 · 2022: $879 · 2023: $504 · 2024: $580 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $856.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $541.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $438.71 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $314.60 | 2019-2022 | |
| Lilly USA, LLC | $313.69 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $306.68 | 2019-2025 | Otezla, Repatha |
| Allergan, INC. | $269.95 | 2019-2020 | |
| Pfizer INC. | $200.10 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $191.26 | 2024 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.30 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.98 | 2019-2023 | Xifaxan |
| Mdd US Operations, LLC | $142.21 | 2019 | |
| Xeris Pharmaceuticals, INC. | $128.59 | 2022-2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $127.08 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.85 | 2024-2025 | Caplyta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Odell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.